Cholesteryl ester transfer protein inhibition and endothelial function: enough with the surrogates.
作者信息
Shah Prediman K
出版信息
Eur Heart J. 2012 Apr;33(7):819-21. doi: 10.1093/eurheartj/ehs040. Epub 2012 Feb 20.
Abstract
摘要
相似文献
1
Cholesteryl ester transfer protein inhibition and endothelial function: enough with the surrogates.
Eur Heart J. 2012 Apr;33(7):819-21. doi: 10.1093/eurheartj/ehs040. Epub 2012 Feb 20.
2
Mulling over the odds of CETP inhibition.
Eur Heart J. 2010 Feb;31(4):390-3. doi: 10.1093/eurheartj/ehp394. Epub 2010 Jan 22.
3
Vascular effects and safety of dalcetrapib in patients with or at risk of coronary heart disease: the dal-VESSEL randomized clinical trial.
Eur Heart J. 2012 Apr;33(7):857-65. doi: 10.1093/eurheartj/ehs019. Epub 2012 Feb 16.
4
Future of cholesteryl ester transfer protein inhibitors.
Annu Rev Med. 2014;65:385-403. doi: 10.1146/annurev-med-050311-163305.
5
Cholesteryl ester transfer protein inhibition to reduce cardiovascular risk: Where are we now?
Trends Pharmacol Sci. 2011 Dec;32(12):694-9. doi: 10.1016/j.tips.2011.07.004. Epub 2011 Nov 14.
6
The controversy over the use of cholesteryl ester transfer protein inhibitors: is there some light at the end of the tunnel?
Eur J Clin Invest. 2016 Jun;46(6):581-9. doi: 10.1111/eci.12626. Epub 2016 Apr 15.
7
Dalcetrapib , a cholesteryl ester transfer protein modulator.
Expert Opin Investig Drugs. 2012 Sep;21(9):1427-32. doi: 10.1517/13543784.2012.699040. Epub 2012 Jun 24.
8
Perspective. The failure of cholesteryl ester transfer protein inhibitors: is it due to increased blood viscosity?
Ther Adv Cardiovasc Dis. 2015 Apr;9(2):32-5. doi: 10.1177/1753944714566427. Epub 2015 Jan 8.
9
Prevention of coronary heart disease with pravastatin.
N Engl J Med. 1996 May 16;334(20):1333-4; author reply 1334-5.
10
Prevention of coronary heart disease with pravastatin.
N Engl J Med. 1996 May 16;334(20):1333; author reply 1334-5. doi: 10.1056/NEJM199605163342013.
本文引用的文献
1
Vascular effects and safety of dalcetrapib in patients with or at risk of coronary heart disease: the dal-VESSEL randomized clinical trial.
Eur Heart J. 2012 Apr;33(7):857-65. doi: 10.1093/eurheartj/ehs019. Epub 2012 Feb 16.
2
New horizons for cholesterol ester transfer protein inhibitors.
Curr Atheroscler Rep. 2012 Feb;14(1):41-8. doi: 10.1007/s11883-011-0217-9.
3
Investigational CETP antagonists for hyperlipidemia and atherosclerosis prevention.
Expert Opin Investig Drugs. 2011 Nov;20(11):1543-54. doi: 10.1517/13543784.2011.614946. Epub 2011 Oct 1.
4
Torcetrapib impairs endothelial function in hypertension.
Eur Heart J. 2012 Jul;33(13):1615-24. doi: 10.1093/eurheartj/ehr348. Epub 2011 Sep 14.
5
Safety and efficacy of dalcetrapib on atherosclerotic disease using novel non-invasive multimodality imaging (dal-PLAQUE): a randomised clinical trial.
Lancet. 2011 Oct 29;378(9802):1547-59. doi: 10.1016/S0140-6736(11)61383-4. Epub 2011 Sep 9.
6
Residual risk and high-density lipoprotein cholesterol levels: is there a relationship?
Rev Cardiovasc Med. 2011;12(2):e55-9.
7
Progress in HDL-based therapies for atherosclerosis.
Curr Atheroscler Rep. 2011 Oct;13(5):405-12. doi: 10.1007/s11883-011-0189-9.
8
Mechanisms underlying adverse effects of HDL on eNOS-activating pathways in patients with coronary artery disease.
J Clin Invest. 2011 Jul;121(7):2693-708. doi: 10.1172/JCI42946. Epub 2011 Jun 23.
9
Safety of anacetrapib in patients with or at high risk for coronary heart disease.
N Engl J Med. 2010 Dec 16;363(25):2406-15. doi: 10.1056/NEJMoa1009744. Epub 2010 Nov 17.
10
Modulating cholesteryl ester transfer protein activity maintains efficient pre-β-HDL formation and increases reverse cholesterol transport.
J Lipid Res. 2010 Dec;51(12):3443-54. doi: 10.1194/jlr.M008706. Epub 2010 Sep 22.
Zotero 插件